多聚腺苷二磷酸核糖聚合酶抑制剂用于晚期卵巢癌维持治疗的不良反应及管理  

Adverse Effects of Poly ADP-Ribose Polymerase Inhibitors in the Treatment of Advanced Ovarian Cancer and Its Management

作　　者：郭涛 尹如铁[1,2] GUO Tao;YIN Rutie(Department of Obstetrics and Gynecology,West China Second Hospital,Sichuan University,Chengdu,Sichuan,610041,China;Education Ministry Key Laboratory of Birth Defects and Related Diseases of Women and Children,Chengdu,Sichuan,610041,China)

机构地区：[1]四川大学华西第二医院妇产科,四川成都610041 [2]西部妇幼研究院出生缺陷与相关妇儿疾病教育部重点实验室,四川成都610041

出　　处：《肿瘤药学》2021年第3期263-268,279,共7页Anti-Tumor Pharmacy

基　　金：四川省科学技术厅重点研发项目妇产科重大疾病诊治关键因素的研究(19ZDYF)。

摘　　要：多聚腺苷二磷酸核糖聚合酶(PARP)抑制剂作为一种新型靶向生物制剂,显著改善了卵巢癌患者的治疗现状,并被国内外多个临床指南推荐用于晚期卵巢癌的维持治疗。目前,国内外已有多种PARP抑制剂上市,其临床应用日益增多,患者发生不良反应的风险也随之增加。全面了解各种PARP抑制剂的毒性特征是确保临床安全用药的基础。本文对PARP抑制剂维持治疗临床研究中报道的不良反应进行综述,并给出相应的管理建议,旨在为卵巢癌患者临床用药提供安全保障。Poly ADP-ribose polymerase(PARP)inhibitors,as a new kind of target biological agent,have significantly improved the treatment status of ovarian cancer patients.Now,PARP inhibitors have been recommended as maintenance therapy for advanced ovarian cancer by several clinical guidelines in the world.With the increasing use of PARP inhibitors,more and more patients are reported occurring adverse events.A comprehensive understanding of the toxicity characteristics of PARP inhibitors is the basis to ensure the safety of clinical drug use.Therefore,in this review,we summarized the adverse reactions reported in the clinical studies of maintenance therapy with PARP inhibitors,and made some corresponding management suggestions,so as to provide safety guarantee for the clinical use of PARP inhibitors in ovarian cancer patients.

关 键 词：PARP抑制剂 晚期卵巢癌 不良反应管理 

分 类 号：R737.31[医药卫生—肿瘤]